Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors

Matjaz Zwitter, Antonio Rossi, Massimo Di Maio, Maja Pohar Perme, Gilberto Lopes

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

When treating patients with advanced non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors and chemotherapy, intercalated schedule with time separation between the two classes of drugs should avoid their mutual antagonism. In a survey of published trials, we focus on relation between eligibility criteria and effectiveness of intercalated treatment. Published documents were identified using major medical databases, conference proceedings and references of published trials. Median progression-free survival (PFS) was taken as the basic parameter of treatment efficacy. Correlation between characteristics of patients and median PFS was assessed through the Pearson's correlation coefficient and the coefficient of determination, separately for first-line and second-line setting. The series includes 11 single-arm trials and 18 randomized phase II or phase III trials with a total of 2903 patients. Treatment-naive patients or those in progression after first-line treatment were included in 16 and 13 trials, respectively. In 14 trials, only patients with non-squamous histology were eligible. Proportion of patients with non-squamous carcinoma (in first-line setting), proportion of never-smokers (both in first- A nd second-line setting) and proportion of epidermal growth factor receptor (EGFR) mutant patients (both in first- A nd second-line setting) showed a moderate or strong correlation with median PFS. In six trials of intercalated treatment applied to treatment-naive EGFR-mutant patients, objective response was confirmed in 83.1% of cases and median PFS was 18.6 months. Most suitable candidates for intercalated treatment are treatment-naive patients with EGFR-mutant tumors, as determined from biopsy or liquid biopsy. For these patients, experience with intercalated treatment is most promising and randomized trials with comparison to the best standard treatment are warranted.

Original languageEnglish
Pages (from-to)241-251
Number of pages11
JournalRadiology and Oncology
Volume51
Issue number3
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Drug Therapy
Disease-Free Survival
Epidermal Growth Factor Receptor
Therapeutics
Biopsy
Histology
Appointments and Schedules
Databases
Carcinoma

Keywords

  • EGFR
  • intercalated treatment
  • NSCLC
  • tyrosine-kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors. / Zwitter, Matjaz; Rossi, Antonio; Di Maio, Massimo; Perme, Maja Pohar; Lopes, Gilberto.

In: Radiology and Oncology, Vol. 51, No. 3, 01.01.2017, p. 241-251.

Research output: Contribution to journalReview article

Zwitter, Matjaz ; Rossi, Antonio ; Di Maio, Massimo ; Perme, Maja Pohar ; Lopes, Gilberto. / Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors. In: Radiology and Oncology. 2017 ; Vol. 51, No. 3. pp. 241-251.
@article{181ba35412d5445384e43006c246b218,
title = "Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors",
abstract = "When treating patients with advanced non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors and chemotherapy, intercalated schedule with time separation between the two classes of drugs should avoid their mutual antagonism. In a survey of published trials, we focus on relation between eligibility criteria and effectiveness of intercalated treatment. Published documents were identified using major medical databases, conference proceedings and references of published trials. Median progression-free survival (PFS) was taken as the basic parameter of treatment efficacy. Correlation between characteristics of patients and median PFS was assessed through the Pearson's correlation coefficient and the coefficient of determination, separately for first-line and second-line setting. The series includes 11 single-arm trials and 18 randomized phase II or phase III trials with a total of 2903 patients. Treatment-naive patients or those in progression after first-line treatment were included in 16 and 13 trials, respectively. In 14 trials, only patients with non-squamous histology were eligible. Proportion of patients with non-squamous carcinoma (in first-line setting), proportion of never-smokers (both in first- A nd second-line setting) and proportion of epidermal growth factor receptor (EGFR) mutant patients (both in first- A nd second-line setting) showed a moderate or strong correlation with median PFS. In six trials of intercalated treatment applied to treatment-naive EGFR-mutant patients, objective response was confirmed in 83.1{\%} of cases and median PFS was 18.6 months. Most suitable candidates for intercalated treatment are treatment-naive patients with EGFR-mutant tumors, as determined from biopsy or liquid biopsy. For these patients, experience with intercalated treatment is most promising and randomized trials with comparison to the best standard treatment are warranted.",
keywords = "EGFR, intercalated treatment, NSCLC, tyrosine-kinase inhibitors",
author = "Matjaz Zwitter and Antonio Rossi and {Di Maio}, Massimo and Perme, {Maja Pohar} and Gilberto Lopes",
year = "2017",
month = "1",
day = "1",
doi = "10.1515/raon-2017-0029",
language = "English",
volume = "51",
pages = "241--251",
journal = "Radiology and Oncology",
issn = "1318-2099",
publisher = "Slovenian Medical Society / Croatian Medical Association",
number = "3",

}

TY - JOUR

T1 - Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors

AU - Zwitter, Matjaz

AU - Rossi, Antonio

AU - Di Maio, Massimo

AU - Perme, Maja Pohar

AU - Lopes, Gilberto

PY - 2017/1/1

Y1 - 2017/1/1

N2 - When treating patients with advanced non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors and chemotherapy, intercalated schedule with time separation between the two classes of drugs should avoid their mutual antagonism. In a survey of published trials, we focus on relation between eligibility criteria and effectiveness of intercalated treatment. Published documents were identified using major medical databases, conference proceedings and references of published trials. Median progression-free survival (PFS) was taken as the basic parameter of treatment efficacy. Correlation between characteristics of patients and median PFS was assessed through the Pearson's correlation coefficient and the coefficient of determination, separately for first-line and second-line setting. The series includes 11 single-arm trials and 18 randomized phase II or phase III trials with a total of 2903 patients. Treatment-naive patients or those in progression after first-line treatment were included in 16 and 13 trials, respectively. In 14 trials, only patients with non-squamous histology were eligible. Proportion of patients with non-squamous carcinoma (in first-line setting), proportion of never-smokers (both in first- A nd second-line setting) and proportion of epidermal growth factor receptor (EGFR) mutant patients (both in first- A nd second-line setting) showed a moderate or strong correlation with median PFS. In six trials of intercalated treatment applied to treatment-naive EGFR-mutant patients, objective response was confirmed in 83.1% of cases and median PFS was 18.6 months. Most suitable candidates for intercalated treatment are treatment-naive patients with EGFR-mutant tumors, as determined from biopsy or liquid biopsy. For these patients, experience with intercalated treatment is most promising and randomized trials with comparison to the best standard treatment are warranted.

AB - When treating patients with advanced non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors and chemotherapy, intercalated schedule with time separation between the two classes of drugs should avoid their mutual antagonism. In a survey of published trials, we focus on relation between eligibility criteria and effectiveness of intercalated treatment. Published documents were identified using major medical databases, conference proceedings and references of published trials. Median progression-free survival (PFS) was taken as the basic parameter of treatment efficacy. Correlation between characteristics of patients and median PFS was assessed through the Pearson's correlation coefficient and the coefficient of determination, separately for first-line and second-line setting. The series includes 11 single-arm trials and 18 randomized phase II or phase III trials with a total of 2903 patients. Treatment-naive patients or those in progression after first-line treatment were included in 16 and 13 trials, respectively. In 14 trials, only patients with non-squamous histology were eligible. Proportion of patients with non-squamous carcinoma (in first-line setting), proportion of never-smokers (both in first- A nd second-line setting) and proportion of epidermal growth factor receptor (EGFR) mutant patients (both in first- A nd second-line setting) showed a moderate or strong correlation with median PFS. In six trials of intercalated treatment applied to treatment-naive EGFR-mutant patients, objective response was confirmed in 83.1% of cases and median PFS was 18.6 months. Most suitable candidates for intercalated treatment are treatment-naive patients with EGFR-mutant tumors, as determined from biopsy or liquid biopsy. For these patients, experience with intercalated treatment is most promising and randomized trials with comparison to the best standard treatment are warranted.

KW - EGFR

KW - intercalated treatment

KW - NSCLC

KW - tyrosine-kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85029624575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029624575&partnerID=8YFLogxK

U2 - 10.1515/raon-2017-0029

DO - 10.1515/raon-2017-0029

M3 - Review article

AN - SCOPUS:85029624575

VL - 51

SP - 241

EP - 251

JO - Radiology and Oncology

JF - Radiology and Oncology

SN - 1318-2099

IS - 3

ER -